Chardan Healthcare Acquisition 2 Corp. Completes Business Combination with Renovacor, Inc.
September 2, 2021
Renovacor, an early‑stage biotechnology company developing AAV‑based gene therapies for BAG3‑associated cardiovascular and CNS diseases, closed a business combination with special purpose acquisition company Chardan Healthcare Acquisition 2 Corp. (CHAQ) and will begin trading on the New York Stock Exchange as Renovacor, Inc., with approximately $95.1 million of gross proceeds (including a $30.0 million PIPE) to fund clinical development into 2023. The transaction preserves Renovacor’s existing management team and provides public-market access and capital to advance its lead program, REN‑001, toward IND submission and a Phase I/II trial.
- Buyers
- Chardan Healthcare Acquisition 2 Corp.
- Targets
- Renovacor, Inc.
- Industry
- Biotechnology
- Location
- Connecticut, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Rocket Pharmaceuticals Acquires Renovacor
September 20, 2022
Biotechnology
Rocket Pharmaceuticals (NASDAQ: RCKT) will acquire Renovacor (NYSE: RCOR) in an all-stock transaction valued at approximately $53 million (implied $2.60 per Renovacor share). The acquisition strengthens Rocket's leadership in AAV-based cardiac gene therapy by adding Renovacor's REN-001 BAG3-targeted program and related capabilities to Rocket's clinical pipeline.
-
Viveon Health Acquisition Corp. to Merge with Suneva Medical
January 12, 2022
Medical Devices
Suneva Medical, a San Diego–based regenerative aesthetics medical technology company, has entered into a definitive merger agreement with special purpose acquisition company Viveon Health Acquisition Corp. The transaction will combine Suneva with the public SPAC vehicle (NYSE American: VHAQ) to provide growth capital and public-market access for Suneva, with the combined company expected to trade on the NYSE under the symbol "RNEW."
-
Keen Vision Acquisition Corporation to Merge with Medera Inc. (NASDAQ Listing)
September 5, 2024
Biotechnology
Keen Vision Acquisition Corporation (KVAC) entered into a definitive merger agreement with clinical-stage biotechnology company Medera Inc. to take Medera public on Nasdaq, expected to close in the fourth quarter of 2024. The business combination is expected to provide funds that will accelerate Medera’s three most advanced AAV-based gene therapy programs.
-
ChrysCapital Acquires Minority Stake in La Renon
April 16, 2024
Pharmaceuticals
India-focused PE firm ChrysCapital is investing about $70 million to acquire a minority stake in Ahmedabad-based pharmaceutical company La Renon. The growth investment will support La Renon's expansion plans across chronic therapeutic segments, strengthen manufacturing and R&D capabilities, and fund geographic expansion into international markets.
-
Novartis AG Acquires Chinook Therapeutics
June 12, 2023
Biotechnology
Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.
-
Novo Nordisk to Acquire Cardior Pharmaceuticals for Up to €1.025 Billion
March 25, 2024
Biotechnology
Novo Nordisk agreed to acquire Cardior Pharmaceuticals for up to €1.025 billion, consisting of an upfront payment plus additional milestone payments tied to development and commercial progress. The deal is expected to strengthen Novo Nordisk’s cardiovascular pipeline, centered on Cardior’s lead candidate CDR132L in phase 2 heart failure trials.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.